s
Curium Announces First Commercial Doses in Italy of PYLCLARI® – An Innovative 18F-PSMA PET Tracer Indicated in Patients With Prostate Cancer
07-03-2024, 15:32
PARIS, March 07, 2024 (GLOBE NEWSWIRE) — Curium, a world leader in nuclear medicine, announced today that the first commercial doses of PYLCLARI® have been sold in Italy. PYLCLARI® (INN: Piflufolastat (18F)) also known as (18 F)-DCFPyL, is indicated for the detection of prostate-specific membrane antigen (PSMA) positive lesions with positron emission tomography (PET) in patients […] L'articolo Curium Announces First Commercial Doses in Italy of PYLCLARI® – An Innovative 18F-PSMA PET Tracer Indicated in Patients With Prostate Cancer proviene da La Ragione.
CONTINUA A LEGGERE
7
0
0
Guarda anche
La Ragione
Ieri, 22:12
Le Pen: “La marea cresce, la nostra vittoria è solo rimandata”
La Ragione
Ieri, 21:03
“Macron deve far governare noi”, così Mélenchon dopo i primi risultati degli exit poll
La Ragione
Ieri, 20:27
La sinistra vince e pone condizioni a Macron, Le Pen solo terza fuori dai giochi
La Ragione
Ieri, 19:43